|
Fred Cohen is a managing director at Texas Pacific Group Ventures, where he initiated their investment efforts in the life sciences. He also retains a position as a Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco. Dr. Cohen also serves as a member of the boards of GenomicHealth, XDx, Kemia, CardioDx, Anaborex and Matrix Pharmaceuticals. He is also a member of the Investment Committee of the Board of Quintiles Transnational. He received his M.D. from Stanford, his D.Phil. in Molecular Biophysics from Oxford as a Rhodes Scholar and his Bachelor's degree from Yale University in Molecular Biophysics and Biochemistry. Dr. Cohen has been a member of the faculty of UCSF since 1986 and is best known for his work on protein structure and the conformational basis of prion disease. He is a member of the Institute of Medicine of the National Academy of Sciences. | 